Steven Koenig, MD
Pulmonary Disease · Morehead, KYNPI 1669513321
Payments from drug & device makers
Across 530 payments — averaging $457.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$228K
- Insmed, Inc.$9K
- AstraZeneca$2K
- Boehringer Ingelheim$732
- Grifols USA, LLC$434
- Gilead$394
- plus $2K from 27 others
What the payments were for
- Consulting fees$84,61835%
- Speaking & faculty fees$123,15051%
- Travel & lodging$25,93311%
- Food & beverage$8,2813%
- Education$3660%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 237 | $227,660 |
| Insmed, Inc. | 12 | $9,470 |
| AstraZeneca | 70 | $1,731 |
| Boehringer Ingelheim | 43 | $732 |
| Grifols USA, LLC | 35 | $434 |
| Gilead | 30 | $394 |
| Regeneron Healthcare Solutions, Inc. | 14 | $305 |
| Mylan Specialty L.p. | 16 | $292 |
| Sanofi | 12 | $250 |
| Jazz Pharmaceuticals Inc. | 9 | $219 |
| Axsome Therapeutics, Inc. | 5 | $137 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $120 |
| Sunovion Pharmaceuticals Inc. | 11 | $103 |
| Merck | 3 | $63 |
| Verona Pharma, Inc. | 3 | $55 |
| Electromed, Inc. | 4 | $52 |
| Fisher & Paykel Healthcare Inc | 1 | $37 |
| Inogen, Inc. | 2 | $33 |
| Pulmonx Corporation | 2 | $32 |
| Amgen | 1 | $25 |
| Baxter Healthcare | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Livanova USA, Inc. | 1 | $20 |
| Harmony Biosciences LLC | 1 | $18 |
| United Therapeutics Corporation | 1 | $18 |
| Vifor Pharma, Inc. | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Mayne Pharma Commercial LLC | 1 | $17 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $16 |
| Shire North American Group Inc | 1 | $14 |
| Biomerieux Inc | 1 | $14 |
| AbbVie | 1 | $14 |
| Intercept Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$56,175
- NUCALA$22,550
- AREXVY$22,358
- ANORO ELLIPTA$3,600
- TEZSPIRE$607
- FASENRA$607
- BREZTRI$443
- AIRSUPRA$164
- BEVESPI AEROSPHERE$155
How this compares
$242,365 in reported general payments places this provider in the 95th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,024 | $918,590 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 24 | $253,343 |
| Dupixent PenDupilumab | 40 | $148,233 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 102 | $83,381 |
| NucalaMepolizumab | 20 | $73,125 |
| Fasenra PenBenralizumab | 12 | $67,334 |
| Breo ElliptaFluticasone/Vilanterol | 96 | $60,248 |
| TezspireTezepelumab-Ekko | 13 | $53,786 |
| Spiriva HandihalerTiotropium Bromide | 38 | $36,172 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 58 | $33,494 |
| Spiriva RespimatTiotropium Bromide | 42 | $33,390 |
| Theophylline ErTheophylline Anhydrous | 367 | $29,135 |
| Arnuity ElliptaFluticasone Furoate | 72 | $19,868 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 24 | $18,323 |
| Roflumilast | 385 | $17,028 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $227,660 | $1,119,3311,294 claims |
| Grifols USA, LLCProlastin C | $434 | $253,34324 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $1,731 | $145,558138 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat | $732 | $62,74082 claims |
| MerckDulera | $63 | $10,84827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Morehead
- John McConnellLouisville$3.5M
- Girish NairLexington$852K
- Sally SulimanLouisville$472K
- Mohamed SaadLouisville$440K
- David WinslowLouisville$431K
- Firas KouraGeorgetown$423K
- Erica GregonisRichmond$390K
- Karim El-KershLouisville$379K
- Harold HallerLouisville$369K
- Samantha BaahLouisville$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.